August 1, 1998Journal of Cardiovascular Pharmacology

Oral Antiplatelet Efficacy and Specificity of a Novel Nonpeptide Platelet GPIIb/IIIa Receptor Antagonist, DMP 802

View Full Paper

Ask AI

Bookmark

Population

Platelets from various species and mongrel dogs

Design

Preclinical

Follow-up

5 days (for repeated dosing in dogs)

Authors

SMShaker A. MousaUniversity of North Carolina at Chapel Hill RORichard E. OlsonLos Alamos National Laboratory JBJeffrey M. BozarthBristol-Myers Squibb (United States)

Discussion

Member takes

Implication

Supports further preclinical development of DMP 802; leaves open translation to human antiplatelet trials.

Structured PICO

Population

Platelets from various species (human, baboon, canine, guinea pig, swine, hamster, rabbit, rat) and mongrel dogs

Intervention

DMP 802 (in vitro assays and oral dosing 0.05-0.20 mg/kg single or 0.05 mg/kg daily for 5 days in dogs)

Outcome

Platelet aggregation inhibition (IC50), receptor binding affinity (Kd), and specificitysurrogate

DMP 802 is a novel oral antiplatelet agent that demonstrates high affinity and specificity for human platelet GPIIb/IIIa receptors with dose-dependent efficacy in canine models.

Cite This Study

Mousa et al. (1998) studied this question.

synapsesocial.com/papers/6a92a2ad8262cd83d96242d4 https://doi.org/10.1097/00005344-199808000-00001

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Oral Antiplatelet Efficacy and Specificity of a Novel Nonpeptide Platelet GPIIb/IIIa Receptor Antagonist, DMP 802

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Oral Antiplatelet Efficacy and Specificity of a Novel Nonpeptide Platelet GPIIb/IIIa Receptor Antagonist, DMP 802

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider